stockrowPrima BioMed Ltd
IMMP Healthcare Biotechnology
Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025.
Follow IMMP
Alert me
Prima BioMed Ltd (IMMP) Altman Z-score
Prima BioMed Ltd's Altman Z-score for fiscal 2026 is 39.33, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | 39.33 | 26.87 |
| FY2025 | 12.46 | (3.62) |
| FY2024 | 16.08 | 3.86 |
| FY2023 | 12.22 | (1.28) |
| FY2022 | 13.50 | (3.11) |
| FY2021 | 16.60 | 21.78 |
| FY2020 | −5.18 | 1.52 |
| FY2019 | −6.70 | (2.94) |
| FY2018 | −3.75 | 1.61 |
| FY2017 | −5.36 | 5.69 |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.80 | — | 0.96 | |
| Retained earnings / total assets | (6.25) | — | −8.76 | |
| EBIT / total assets | (0.93) | — | −3.07 | |
| Market value of equity / total liabilities | 83.18 | — | 49.91 | |
| Sales / total assets | 0.29 | — | 0.29 | |
| Altman Z-score | Safe zone | 39.33 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −18.43 | ||
Z and Z″ put Prima BioMed Ltd in different zones: safe zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| IMMP Prima BioMed Ltd | 39.3× |
| COCP Cocrystal Pharma, Inc. compare | 19.8× |
| CRVO CervoMed Inc. compare | 0.3× |
| MCRB Seres Therapeutics, Inc. compare | −11.0× |
| ATOS Atossa Therapeutics, Inc. compare | −15.6× |
| ACTU Actuate Therapeutics, Inc. compare | — |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | — |
| BSEM BioStem Technologies, Inc. compare | — |
| FLNA Cassava Sciences, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets